Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT06945146 2025-04-25

CAP

Completed

65 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03690115 2025-03-25

PONALLO

Phase 2 Completed

23 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02272998 2025-03-24

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Phase 2 Completed

22 enrolled 13 charts

Neoplasms, Piebaldism

NCT01935336 2022-02-11

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

Phase 2 Completed

171 enrolled 13 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Small Cell Lung Carcinoma

NCT02265341 2020-11-25

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

Phase 2 Completed

12 enrolled 11 charts

Gastrointestinal

Malignant Hepatobiliary Neoplasm

NCT02779283 2020-05-26

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Phase 1 Completed

7 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01813734 2019-12-24

Ponatinib in Advanced NSCLC w/ RET Translocations

Phase 2 Completed

9 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02478164 2018-07-24

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

Phase 2 Completed

17 enrolled 13 charts

CNS

Glioblastoma

NCT02981784 2016-12-05

Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I

Completed

184 enrolled

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

CAP

PONALLO

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Ponatinib in Advanced NSCLC w/ RET Translocations

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I